Eli Lilly’s Obesity Drug Retatrutide Leads To 24.2% Weight Loss In Phase 2 Trial
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Eli Lilly and Co. (LLY) said results from phase 2 clinical trial showed that people treated with the highest dose of retatrutide achieved a mean weight reduction of 24.2% at the end of the 48-week. This translates to an average absolute weight reduction of about 58 po
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-942149588-c1f08ddba9c4491eb02bd6c1a76b0117.jpg "How to Cope with 10 Coworker Personality Types")
